Literature DB >> 10386624

Structure-function analysis of a double-mutant cystic fibrosis transmembrane conductance regulator protein occurring in disorders related to cystic fibrosis.

P Fanen1, J Clain, R Labarthe, P Hulin, E Girodon, P Pagesy, M Goossens, A Edelman.   

Abstract

A number of disorders related to cystic fibrosis have been described since the cloning of the cystic fibrosis gene, including infertility due to the congenital bilateral absence of the vas deferens. We have identified, in several patients, complex cystic fibrosis transmembrane conductance regulator genotypes like double-mutant alleles. We have now analyzed the structure-function relationships of one of these mutants, R74W-D1270N cystic fibrosis transmembrane conductance regulator, expressed in HeLa cells, to evaluate the contribution of each mutation in the phenotype. We found that R74W cystic fibrosis transmembrane conductance regulator appears to be a polymorphism, while D1270N cystic fibrosis transmembrane conductance regulator could be responsible for the congenital bilateral absence of the vas deferens phenotype. The combination of the two produced a more severe effect on the chloride conductance pathway as well as on the phenotype.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10386624     DOI: 10.1016/s0014-5793(99)00647-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  The novel complex allele [A238V;F508del] of the CFTR gene: clinical phenotype and possible implications for cystic fibrosis etiological therapies.

Authors:  Anna Diana; Angela Maria Polizzi; Teresa Santostasi; Luigi Ratclif; Maria Giuseppina Pantaleo; Giuseppina Leonetti; Danila Rosa Iusco; Crescenzio Gallo; Massimo Conese; Antonio Manca
Journal:  J Hum Genet       Date:  2016-02-25       Impact factor: 3.172

2.  Genotype-phenotype correlation for pulmonary function in cystic fibrosis.

Authors:  J de Gracia; F Mata; A Alvarez; T Casals; S Gatner; M Vendrell; D de la Rosa; L Guarner; E Hermosilla
Journal:  Thorax       Date:  2005-07       Impact factor: 9.139

3.  RNF185 is a novel E3 ligase of endoplasmic reticulum-associated degradation (ERAD) that targets cystic fibrosis transmembrane conductance regulator (CFTR).

Authors:  Elma El Khouri; Gwenaëlle Le Pavec; Michel B Toledano; Agnès Delaunay-Moisan
Journal:  J Biol Chem       Date:  2013-09-09       Impact factor: 5.157

4.  Effects of cystic fibrosis and congenital bilateral absence of the vas deferens-associated mutations on cystic fibrosis transmembrane conductance regulator-mediated regulation of separate channels.

Authors:  J E Mickle; M I Milewski; M Macek; G R Cutting
Journal:  Am J Hum Genet       Date:  2000-04-04       Impact factor: 11.025

5.  p.Ser1235Arg should no longer be considered as a cystic fibrosis mutation: results from a large collaborative study.

Authors:  Céline René; Damien Paulet; Emmanuelle Girodon; Catherine Costa; Guy Lalau; Julie Leclerc; Faïza Cabet-Bey; Thierry Bienvenu; Martine Blayau; Albert Iron; Hervé Mittre; Delphine Feldmann; Caroline Guittard; Mireille Claustres; Marie des Georges
Journal:  Eur J Hum Genet       Date:  2010-08-18       Impact factor: 4.246

6.  Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR.

Authors:  Nesrine Baatallah; Ahmad Elbahnsi; Isabelle Callebaut; Alexandre Hinzpeter; Jean-Paul Mornon; Benoit Chevalier; Iwona Pranke; Nathalie Servel; Renaud Zelli; Jean-Luc Décout; Aleksander Edelman; Isabelle Sermet-Gaudelus
Journal:  Cell Mol Life Sci       Date:  2021-10-29       Impact factor: 9.261

7.  A neutral variant involved in a complex CFTR allele contributes to a severe cystic fibrosis phenotype.

Authors:  Jérôme Clain; Jacqueline Lehmann-Che; Emmanuelle Girodon; Joanna Lipecka; Aleksander Edelman; Michel Goossens; Pascale Fanen
Journal:  Hum Genet       Date:  2005-03-03       Impact factor: 4.132

8.  Alternative splicing at a NAGNAG acceptor site as a novel phenotype modifier.

Authors:  Alexandre Hinzpeter; Abdel Aissat; Elvira Sondo; Catherine Costa; Nicole Arous; Christine Gameiro; Natacha Martin; Agathe Tarze; Laurence Weiss; Alix de Becdelièvre; Bruno Costes; Michel Goossens; Luis J Galietta; Emmanuelle Girodon; Pascale Fanen
Journal:  PLoS Genet       Date:  2010-10-07       Impact factor: 5.917

9.  Factors influencing readthrough therapy for frequent cystic fibrosis premature termination codons.

Authors:  Iwona Pranke; Laure Bidou; Natacha Martin; Sandra Blanchet; Aurélie Hatton; Sabrina Karri; David Cornu; Bruno Costes; Benoit Chevalier; Danielle Tondelier; Emmanuelle Girodon; Matthieu Coupet; Aleksander Edelman; Pascale Fanen; Olivier Namy; Isabelle Sermet-Gaudelus; Alexandre Hinzpeter
Journal:  ERJ Open Res       Date:  2018-02-23

10.  Are p.I148T, p.R74W and p.D1270N cystic fibrosis causing mutations?

Authors:  Mireille Claustres; Jean-Pierre Altiéri; Caroline Guittard; Carine Templin; Françoise Chevalier-Porst; Marie Des Georges
Journal:  BMC Med Genet       Date:  2004-08-02       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.